Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
Paul M. Friedman, MD - Dermatologist in Houston and New York Click here for high-resolution version HOUSTON, TX--(Marketwired - Jun 5, 2014) - Dr. Paul M. Friedman, a board-certified dermatologist in ...
The US Food and Drug Administration (FDA) has approved Juvéderm Voluma XC (Allergan) to correct age-related volume deficits in the midface in adults aged 21 years and older, the company announced ...
Hyaluronic acid 20mg/mL, 0.3% w/w lidocaine; injectable gel implant. Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to ...
NEWPORT BEACH, CA--(Marketwired - Sep 22, 2015) - Dr. Nancy Silverberg, a dermatologist in Newport Beach, believes that looking younger can help patients feel younger, which can improve their overall ...
Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...
IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results